Ellen Holm Nielsen
Corporate Officer/Principal presso University of Southern Denmark
Posizioni attive di Ellen Holm Nielsen
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| University of Southern Denmark | Corporate Officer/Principal | - | - |
| University of California, Berkeley | Corporate Officer/Principal | - | - |
| Albert Einstein College of Medicine, Inc. | Corporate Officer/Principal | 14/08/2009 | - |
| University of Copenhagen | Corporate Officer/Principal | - | - |
Storia della carriera di Ellen Holm Nielsen
Precedenti posizioni note di Ellen Holm Nielsen
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Profylakse ApS
 Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations. | Direttore/Membro del Consiglio | - | 22/11/2013 |
Statistiche
Distribuzione geografica
| Danimarca | 4 |
| Stati Uniti | 3 |
Posizioni
| Corporate Officer/Principal | 4 |
| Director/Board Member | 1 |
Settori
| Consumer Services | 5 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Profylakse ApS
Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations. | Health Technology |
- Borsa valori
- Insiders
- Ellen Holm Nielsen
- Esperienza
